The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Preclinical Differentiation between Apparently Safe and Potentially Hepatotoxic Applications of TRAIL Either Alone or in Combination with Chemotherapeutic Drugs
Open accessAbstract
Purpose: Tumor necrosis factor-related apoptosis–inducing ligand (TRAIL/Apo2L) exhibits potent antitumor activity on systemic administration in nonhuman primates without deleterious side effects for normal tissue. However, there is a controversy about the potential toxicity of TRAIL on human hepatocytes. The use of different recombinant TRAIL forms only partially explains the contradicting reports on TRAIL sensitivity in primary human hepatocytes (PHH). Experimental Design: To clarify this issue, we comprehensively tested four different recombinant forms of TRAIL for their apoptosis-inducing capacity on PHH obtained from a total of 55 human livers between day 1 and day 8 of in vitro culture. Results: One day after single-cell isolation, all but one recombinant form of TRAIL [i.e., an untagged form of TRAIL (TRAIL.0)] induced apoptosis in PHH. Apoptosis induction by TRAIL in these cells could only be fully inhibited by concomitant blockade of TRAIL receptor 1 and TRAIL receptor 2. At day 4 of in vitro culture, when surrogate markers indicated optimal hepatocyte in vitro function, only high doses of cross-linked FLAG-TRAIL killed PHH whereas the other three recombinant TRAIL forms did not. Strikingly, cotreatment of day 4 PHH with cisplatin sensitized for TRAIL-induced apoptosis whereas 5-fluorouracil, etoposide, gemcitabine, irinotecan, or oxaliplatin, which are commonly used in the treatment of gastrointestinal cancers, did not. Conclusion: Our data show that whereas TRAIL alone or together with selected chemotherapeutic drugs seems to be safe, the combination of TRAIL with cisplatin is toxic to PHH.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Identification and characterization of a new member of the TNF family that induces apoptosis
Wiley, S. R., Schooley, K., Smolak, P. J., Din, W. S., Huang, C.-P., Nicholl, J. K., Sutherland, G. R., Smith, T. D., Rauch, C., Smith, C. A., et al. (1995) · Immunity · doi:10.1016/1074-7613(95)90057-8 · Cited by 2,900
Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo.
Walczak, H., Miller, R. E., Ariail, K., Gliniak, B., Griffith, T. S., Kubin, M., Chin, W., Jones, J., Woodward, A., Le, T., et al. (1999) · Nature Medicine · doi:10.1038/5517 · Cited by 2,497
Self-citationHepatocytes in collagen sandwich: evidence for transcriptional and translational regulation.
Dunn, J. C., Tompkins, R. G., & Yarmush, M. L. (1992) · The Journal of cell biology · doi:10.1083/jcb.116.4.1043 · Cited by 295
Cited by
Life and death by death receptors
Guicciardi, M. E., & Gores, G. J. (2009) · The FASEB Journal · doi:10.1096/fj.08-111005 · Cited by 690
Exploring the TRAILs less travelled: TRAIL in cancer biology and therapy
von Karstedt, S., Montinaro, A., & Walczak, H. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2017.28 · Cited by 556
Self-citationTRAIL signalling: Decisions between life and death
Falschlehner, C., Emmerich, C. H., Gerlach, B., & Walczak, H. (2007) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2007.02.007 · Cited by 458
Self-citationGetting TRAIL back on track for cancer therapy
Lemke, J., von Karstedt, S., Zinngrebe, J., & Walczak, H. (2014) · Cell Death & Differentiation · doi:10.1038/cdd.2014.81 · Cited by 457
Self-citationDirecting cancer cells to self-destruct with pro-apoptotic receptor agonists
Ashkenazi, A. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2637 · Cited by 432
Metadata
- Authors
- Ganten, T. M., Koschny, R., Sykora, J., Schulze-Bergkamen, H., Büchler, P., Haas, T. L., Schader, M. B., Untergasser, A., Stremmel, W., & Walczak, H.
- Venue
- Clinical Cancer Research
- Published
- 2006-04-15
- Volume
- 12
- Issue
- 8
- Pages
- 2640-2646
- ISSN
- 1078-0432 (ISSN-L)
- 1557-3265
- OpenAlex
- W2108902725
- Cited by
- 217
- References
- 3
- FWCI
- 7.86
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Preclinical Differentiation between Apparently Safe and Potentially Hepatotoxic Applications of TRAIL Either Alone or in Combination with Chemotherapeutic Drugs. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-05-2635
- The paper
- Ganten, T. M., Koschny, R., Sykora, J., Schulze-Bergkamen, H., Büchler, P., Haas, T. L., Schader, M. B., Untergasser, A., Stremmel, W., & Walczak, H. (2006). Preclinical Differentiation between Apparently Safe and Potentially Hepatotoxic Applications of TRAIL Either Alone or in Combination with Chemotherapeutic Drugs. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-05-2635
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.